For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the emergence of Vyndamax and Tafamidis meglumine represents a significant breakthrough . These groundbreaking therapies protect the transthyretin protein, halting its harmful build-up and reducing the impact of the illness. Individuals are now reporti